Many pharmaceutical companies are trying to develop drugs for different rare and ultra-rare diseases. To advance product to the next stage of clinical or commercial development, which will be require significant investments, pharma companies aim to make decisions based on projected financial performance of the product by using NPV and ROI analysis. One of most important and most challenging steps in financial valuation is understanding the commercial potentials of the product. Indeed, product forecast is viewed as the most crucial and inevitable part of the valuation process.
This presentation will focus on the unique challenges that rare diseases pose for assessment and forecasting of orphan drugs, different tools to overcome the challenges faced by industry when identifying relevant data sources to evaluate orphan products, outline strengths and limitations of available methods as well as what could be done differently to help improve outcomes.
And yet, programs offering help have a surprisingly low participation rate. At-risk families fear not only hunger, but losing custody of children if their situation is discovered. This case study explores research strategies designed to overcome fear and secrecy in order to assess potential interventions.
care community, including those pertaining to digital healthcare platforms and their expected impact on their profession, both positive and negative.
This paper proposes a predictive modelling and advanced analytics framework, leveraging machine learning and automation principles to assess past trends (tracking results) and deliver forward-looking insight at scale. The result is enhanced understanding, and the ability for sales and marketing teams to identify which actions will have the greatest impact on brand performance, leading to more actionable brand management.
The idea that a patient’s own cells can be reprogrammed to attack cancer cells or viruses can be used to repair faulty genes is a paradigm shift in medicine. However, a key challenge for all players and drug-makers in this field remains: significant cost of manufacturing, high price tags and the uncertainty around the market acceptance and uptake make it hard to forecast the potential of these innovative therapies. In this presentation, Fatma Aybegum Senkesen will introduce the audience to the basics of the science behind these therapies and also review how both conventional and innovative methods can be utilized to project the future of this innovative market.
Is pharma is different? Can we gain insights into patients and physician from the internet? Are they a representative sample who can we answers our key business questions?